Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update
Cardiff Oncology reported positive Phase 2 data for onvansertib plus FOLFIRI/bevacizumab in first-line RAS-mutated mCRC, showing a confirmed objective response rate of 72.2% compared to 42.1% for standard-of-care alone. Following a successful End-of-Phase 2 meeting with the FDA, the company plans to initiate a registrational Phase 3 trial in Q1 2027, though the start is subject to securing additional financing.
Key figures
- Revenue
- 145000
- Cash Runway
- Q3 2027
- Op ex 6m
- 22600000
- Net loss 6m
- 21589000
- Orr control
- 42.1%
- Cash position
- 34500000
- Orr treatment
- 72.2%
- Offering amount
- 10000000
- Pfs hazard ratio
- 0.55
- Net cash used ops 6m
- 24100000
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.